Research Topics
Species | Andreas D KistlerSummaryAffiliation: University Hospital Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric studyAndreas D Kistler
Division of Nephrology, University Hospital, Zurich, Switzerland
PLoS ONE 8:e53016. 2013..In conclusion, the performance of peptidomic biomarker scores is superior to any other biochemical markers of ADPKD and the proteomic biomarker patterns are a promising tool for prognostic evaluation of ADPKD...
Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney diseaseAndreas D Kistler
Department of Nephrology, University Hospital, Zurich, Switzerland
Kidney Int 76:89-96. 2009..These findings present a potential hypothesis for the mechanisms of disease progression in ADPKD which will need to be confirmed by further studies...- Sirolimus and kidney growth in autosomal dominant polycystic kidney diseaseAndreas L Serra
Division of Nephrology, University Hospital and the University of Zurich, Zurich, Switzerland
N Engl J Med 363:820-9. 2010..In autosomal dominant polycystic kidney disease (ADPKD), aberrant activation of the mammalian target of rapamycin (mTOR) pathway is associated with progressive kidney enlargement. The drug sirolimus suppresses mTOR signaling... - Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney diseaseAndreas L Serra
Division of Nephrology, University Hospital Zurich, Institute of Physiology, Switzerland
Nephrol Dial Transplant 24:3334-42. 2009..Here we report the preliminary safety results of the first 6 months of treatment... - Soluble klotho and autosomal dominant polycystic kidney diseaseIvana Pavik
Institute of Physiology and Zurich Center for Integrative Human Physiology, Zurich, Switzerland
Clin J Am Soc Nephrol 7:248-57. 2012..This study explored potential mechanisms underlying resistance to FGF23 in ADPKD... - Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 monthsAndreas D Kistler
Clinic for Nephrology, University Hospital, Zurich, Switzerland
Kidney Int 75:235-41. 2009..Our study shows that increases in kidney volume can be reliably measured over a 6 month period in early autosomal dominant polycystic kidney disease using unenhanced magnetic resonance imaging sequences... - Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case seriesDiane Poster
Division of Nephrology, University Hospital, Zurich, Switzerland
Am J Kidney Dis 54:450-8. 2009..Whether unilateral ADPKD is associated with faster disease progression is not known... - Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphateIvana Pavik
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
Kidney Int 79:234-40. 2011..The mechanism for this anomaly will require further study... - Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trialMatthias Braun
Division of Nephrology, University Hospital, Zurich, Switzerland
PLoS ONE 7:e45868. 2012..TRIAL REGISTRATION: ClinicalTrials.gov NCT00346918... - Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacyRudolf P Wuthrich
Division of Nephrology, University Hospital, Zurich, Switzerland
Kidney Blood Press Res 32:380-7. 2009..The present review will discuss the utility and the techniques for kidney and cyst volume measurements to assess disease progression in ADPKD, and summarizes ongoing clinical trials testing novel therapeutic options... - A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapyAndreas D Kistler
Division of Nephrology, University Hospital, Zurich, Switzerland
PLoS ONE 6:e20534. 2011..In conclusion, we defined a urinary biomarker model that seems to be of diagnostic use for Fabry disease in female patients and may be used to monitor response to enzyme replacement therapy... - Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD studyAndreas L Serra
Clinic for Nephrology, University Hospital, CH 8091 Zurich, Switzerland
BMC Nephrol 8:13. 2007..Based on these promising results in animals we have designed and initiated the first randomized controlled trial (RCT) to examine the effectiveness, safety and tolerability of sirolimus to retard disease progression in ADPKD...